JP2006524711A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006524711A5 JP2006524711A5 JP2006513387A JP2006513387A JP2006524711A5 JP 2006524711 A5 JP2006524711 A5 JP 2006524711A5 JP 2006513387 A JP2006513387 A JP 2006513387A JP 2006513387 A JP2006513387 A JP 2006513387A JP 2006524711 A5 JP2006524711 A5 JP 2006524711A5
- Authority
- JP
- Japan
- Prior art keywords
- conjugate
- alkyl
- substituted
- composition
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000562 conjugate Substances 0.000 claims 225
- 125000000217 alkyl group Chemical group 0.000 claims 101
- 239000000203 mixture Substances 0.000 claims 83
- 150000003839 salts Chemical class 0.000 claims 47
- 239000012453 solvate Substances 0.000 claims 45
- 125000003545 alkoxy group Chemical group 0.000 claims 43
- 125000000623 heterocyclic group Chemical group 0.000 claims 42
- 229910052760 oxygen Inorganic materials 0.000 claims 40
- 150000001875 compounds Chemical class 0.000 claims 38
- 229910052739 hydrogen Inorganic materials 0.000 claims 36
- -1 NH 2 Inorganic materials 0.000 claims 33
- 229910052799 carbon Inorganic materials 0.000 claims 31
- 125000003342 alkenyl group Chemical group 0.000 claims 30
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 29
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 27
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 26
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 26
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 26
- 229910052757 nitrogen Inorganic materials 0.000 claims 25
- 125000003282 alkyl amino group Chemical group 0.000 claims 24
- 229910052717 sulfur Inorganic materials 0.000 claims 24
- 125000004432 carbon atom Chemical group C* 0.000 claims 23
- 229910052801 chlorine Inorganic materials 0.000 claims 23
- 229910052731 fluorine Inorganic materials 0.000 claims 22
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 125000006239 protecting group Chemical group 0.000 claims 22
- 125000004650 C1-C8 alkynyl group Chemical group 0.000 claims 21
- 229910004013 NO 2 Inorganic materials 0.000 claims 21
- 230000000694 effects Effects 0.000 claims 20
- 125000000547 substituted alkyl group Chemical group 0.000 claims 20
- 125000001153 fluoro group Chemical group F* 0.000 claims 19
- PZOUSPYUWWUPPK-UHFFFAOYSA-N 4-methyl-1h-indole Chemical compound CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 18
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 claims 18
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 claims 18
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 claims 18
- 125000003118 aryl group Chemical group 0.000 claims 18
- 125000005843 halogen group Chemical group 0.000 claims 18
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims 18
- 239000003112 inhibitor Substances 0.000 claims 18
- DRAVOWXCEBXPTN-UHFFFAOYSA-N isoguanine Chemical compound NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 claims 18
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 18
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 18
- 125000003107 substituted aryl group Chemical group 0.000 claims 18
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 18
- 229910052794 bromium Inorganic materials 0.000 claims 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims 16
- 229940035893 uracil Drugs 0.000 claims 15
- 229930024421 Adenine Natural products 0.000 claims 14
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 14
- 229960000643 adenine Drugs 0.000 claims 14
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 14
- 150000008052 alkyl sulfonates Chemical class 0.000 claims 14
- 229940104302 cytosine Drugs 0.000 claims 14
- 229910052740 iodine Inorganic materials 0.000 claims 14
- 239000000651 prodrug Substances 0.000 claims 14
- 229940002612 prodrug Drugs 0.000 claims 14
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 claims 13
- 241001465754 Metazoa Species 0.000 claims 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 13
- 238000000034 method Methods 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 13
- 229940113082 thymine Drugs 0.000 claims 13
- 230000003834 intracellular effect Effects 0.000 claims 12
- 210000000265 leukocyte Anatomy 0.000 claims 12
- 239000002207 metabolite Substances 0.000 claims 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 12
- 229930010555 Inosine Natural products 0.000 claims 11
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims 11
- 229960003786 inosine Drugs 0.000 claims 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 11
- 208000024891 symptom Diseases 0.000 claims 11
- XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 claims 9
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 claims 9
- HCGYMSSYSAKGPK-UHFFFAOYSA-N 2-nitro-1h-indole Chemical compound C1=CC=C2NC([N+](=O)[O-])=CC2=C1 HCGYMSSYSAKGPK-UHFFFAOYSA-N 0.000 claims 9
- FTBBGQKRYUTLMP-UHFFFAOYSA-N 2-nitro-1h-pyrrole Chemical compound [O-][N+](=O)C1=CC=CN1 FTBBGQKRYUTLMP-UHFFFAOYSA-N 0.000 claims 9
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 claims 9
- NBAKTGXDIBVZOO-UHFFFAOYSA-N 5,6-dihydrothymine Chemical compound CC1CNC(=O)NC1=O NBAKTGXDIBVZOO-UHFFFAOYSA-N 0.000 claims 9
- GSPMCUUYNASDHM-UHFFFAOYSA-N 5-methyl-4-sulfanylidene-1h-pyrimidin-2-one Chemical compound CC1=CNC(=O)N=C1S GSPMCUUYNASDHM-UHFFFAOYSA-N 0.000 claims 9
- BXJHWYVXLGLDMZ-UHFFFAOYSA-N 6-O-methylguanine Chemical compound COC1=NC(N)=NC2=C1NC=N2 BXJHWYVXLGLDMZ-UHFFFAOYSA-N 0.000 claims 9
- QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1h-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 claims 9
- RYYIULNRIVUMTQ-UHFFFAOYSA-N 6-chloroguanine Chemical compound NC1=NC(Cl)=C2N=CNC2=N1 RYYIULNRIVUMTQ-UHFFFAOYSA-N 0.000 claims 9
- LHCPRYRLDOSKHK-UHFFFAOYSA-N 7-deaza-8-aza-adenine Chemical compound NC1=NC=NC2=C1C=NN2 LHCPRYRLDOSKHK-UHFFFAOYSA-N 0.000 claims 9
- 229960005508 8-azaguanine Drugs 0.000 claims 9
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims 9
- NWUTZAVMDAGNIG-UHFFFAOYSA-N O(4)-methylthymine Chemical compound COC=1NC(=O)N=CC=1C NWUTZAVMDAGNIG-UHFFFAOYSA-N 0.000 claims 9
- 229930185560 Pseudouridine Natural products 0.000 claims 9
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 claims 9
- 208000036142 Viral infection Diseases 0.000 claims 9
- 230000000840 anti-viral effect Effects 0.000 claims 9
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 9
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 claims 9
- 125000002837 carbocyclic group Chemical group 0.000 claims 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims 9
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims 9
- HBCQSNAFLVXVAY-UHFFFAOYSA-N pyrimidine-2-thiol Chemical compound SC1=NC=CC=N1 HBCQSNAFLVXVAY-UHFFFAOYSA-N 0.000 claims 9
- 229960003087 tioguanine Drugs 0.000 claims 9
- 150000003852 triazoles Chemical class 0.000 claims 9
- 230000009385 viral infection Effects 0.000 claims 9
- 150000001356 alkyl thiols Chemical class 0.000 claims 8
- 125000004663 dialkyl amino group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 150000003951 lactams Chemical class 0.000 claims 8
- 150000002596 lactones Chemical class 0.000 claims 8
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 claims 8
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 8
- QUKPALAWEPMWOS-UHFFFAOYSA-N 1h-pyrazolo[3,4-d]pyrimidine Chemical class C1=NC=C2C=NNC2=N1 QUKPALAWEPMWOS-UHFFFAOYSA-N 0.000 claims 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 7
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 7
- 125000000304 alkynyl group Chemical group 0.000 claims 7
- 150000001408 amides Chemical class 0.000 claims 7
- 125000005110 aryl thio group Chemical group 0.000 claims 7
- 150000007942 carboxylates Chemical class 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 150000002148 esters Chemical class 0.000 claims 7
- 208000015181 infectious disease Diseases 0.000 claims 7
- 230000002401 inhibitory effect Effects 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000005208 trialkylammonium group Chemical group 0.000 claims 7
- SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 claims 6
- 125000005360 alkyl sulfoxide group Chemical group 0.000 claims 6
- 125000004414 alkyl thio group Chemical group 0.000 claims 6
- 125000005361 aryl sulfoxide group Chemical group 0.000 claims 6
- 238000006243 chemical reaction Methods 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- HPZMWTNATZPBIH-UHFFFAOYSA-N methyl adenine Natural products CN1C=NC2=NC=NC2=C1N HPZMWTNATZPBIH-UHFFFAOYSA-N 0.000 claims 6
- 150000002825 nitriles Chemical class 0.000 claims 6
- 229940124530 sulfonamide Drugs 0.000 claims 6
- 150000003456 sulfonamides Chemical class 0.000 claims 6
- 229910019946 S-S Inorganic materials 0.000 claims 5
- 229910019939 S—S Inorganic materials 0.000 claims 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 125000004043 oxo group Chemical group O=* 0.000 claims 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 4
- 125000003302 alkenyloxy group Chemical group 0.000 claims 4
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 4
- 230000002924 anti-infective effect Effects 0.000 claims 4
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 4
- 150000001540 azides Chemical class 0.000 claims 4
- 229910052796 boron Inorganic materials 0.000 claims 4
- 150000001721 carbon Chemical group 0.000 claims 4
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 125000004434 sulfur atom Chemical group 0.000 claims 4
- CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 3
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 3
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 108060004795 Methyltransferase Proteins 0.000 claims 3
- MRWXACSTFXYYMV-UHFFFAOYSA-N Nebularine Natural products OC1C(O)C(CO)OC1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-UHFFFAOYSA-N 0.000 claims 3
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 3
- 229960005475 antiinfective agent Drugs 0.000 claims 3
- 125000004104 aryloxy group Chemical group 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 239000004030 hiv protease inhibitor Substances 0.000 claims 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 3
- 239000002955 immunomodulating agent Substances 0.000 claims 3
- 229940121354 immunomodulator Drugs 0.000 claims 3
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 3
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims 3
- 150000003254 radicals Chemical class 0.000 claims 3
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 3
- 239000003730 rna directed rna polymerase inhibitor Substances 0.000 claims 3
- 230000008685 targeting Effects 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
- VKKXEIQIGGPMHT-UHFFFAOYSA-N 7h-purine-2,8-diamine Chemical compound NC1=NC=C2NC(N)=NC2=N1 VKKXEIQIGGPMHT-UHFFFAOYSA-N 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000012491 analyte Substances 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 2
- 125000005362 aryl sulfone group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 229960000329 ribavirin Drugs 0.000 claims 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 229960004441 tyrosine Drugs 0.000 claims 2
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000005862 (C1-C6)alkanoyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims 1
- 229940099797 HIV integrase inhibitor Drugs 0.000 claims 1
- 101710200424 Inosine-5'-monophosphate dehydrogenase Proteins 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 150000005215 alkyl ethers Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000004419 alkynylene group Chemical group 0.000 claims 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 150000008378 aryl ethers Chemical group 0.000 claims 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 1
- 229960005261 aspartic acid Drugs 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims 1
- KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical compound [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 claims 1
- 150000003857 carboxamides Chemical group 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 1
- 229960002885 histidine Drugs 0.000 claims 1
- 239000003084 hiv integrase inhibitor Substances 0.000 claims 1
- 150000002430 hydrocarbons Chemical group 0.000 claims 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000000863 peptide conjugate Substances 0.000 claims 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Chemical group O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Chemical group 0.000 claims 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical group [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 1
- 125000004437 phosphorous atom Chemical group 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims 1
- 229920002643 polyglutamic acid Polymers 0.000 claims 1
- 108010050934 polyleucine Proteins 0.000 claims 1
- 108010055896 polyornithine Proteins 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108010000222 polyserine Proteins 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 229930195734 saturated hydrocarbon Natural products 0.000 claims 1
- QULKDBMYSOOKMH-UHFFFAOYSA-N sulfo hydrogen carbonate Chemical compound OC(=O)OS(O)(=O)=O QULKDBMYSOOKMH-UHFFFAOYSA-N 0.000 claims 1
- 125000001273 sulfonato group Chemical class [O-]S(*)(=O)=O 0.000 claims 1
- 229960002898 threonine Drugs 0.000 claims 1
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 0 CCCC(C)(C)C(*)(*)[C@](*)(CC=C)C(N**)IC Chemical compound CCCC(C)(C)C(*)(*)[C@](*)(CC=C)C(N**)IC 0.000 description 2
Applications Claiming Priority (183)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46575903P | 2003-04-25 | 2003-04-25 | |
| US46555303P | 2003-04-25 | 2003-04-25 | |
| US46559103P | 2003-04-25 | 2003-04-25 | |
| US46563403P | 2003-04-25 | 2003-04-25 | |
| US46574203P | 2003-04-25 | 2003-04-25 | |
| US46561003P | 2003-04-25 | 2003-04-25 | |
| US46582103P | 2003-04-25 | 2003-04-25 | |
| US46553703P | 2003-04-25 | 2003-04-25 | |
| US46569803P | 2003-04-25 | 2003-04-25 | |
| US46558403P | 2003-04-25 | 2003-04-25 | |
| US46534703P | 2003-04-25 | 2003-04-25 | |
| US46569603P | 2003-04-25 | 2003-04-25 | |
| US46540003P | 2003-04-25 | 2003-04-25 | |
| US46546303P | 2003-04-25 | 2003-04-25 | |
| US46528903P | 2003-04-25 | 2003-04-25 | |
| US46555003P | 2003-04-25 | 2003-04-25 | |
| US46566703P | 2003-04-25 | 2003-04-25 | |
| US46563303P | 2003-04-25 | 2003-04-25 | |
| US46559803P | 2003-04-25 | 2003-04-25 | |
| US46563003P | 2003-04-25 | 2003-04-25 | |
| US46564903P | 2003-04-25 | 2003-04-25 | |
| US46560803P | 2003-04-25 | 2003-04-25 | |
| US46532203P | 2003-04-25 | 2003-04-25 | |
| US46568403P | 2003-04-25 | 2003-04-25 | |
| US46556103P | 2003-04-25 | 2003-04-25 | |
| US46546903P | 2003-04-25 | 2003-04-25 | |
| US46560003P | 2003-04-25 | 2003-04-25 | |
| US46547803P | 2003-04-25 | 2003-04-25 | |
| US46564703P | 2003-04-25 | 2003-04-25 | |
| US46537703P | 2003-04-25 | 2003-04-25 | |
| US46555403P | 2003-04-25 | 2003-04-25 | |
| US46569003P | 2003-04-25 | 2003-04-25 | |
| US46558703P | 2003-04-25 | 2003-04-25 | |
| US46568703P | 2003-04-25 | 2003-04-25 | |
| US46584403P | 2003-04-25 | 2003-04-25 | |
| US46572003P | 2003-04-25 | 2003-04-25 | |
| US46555903P | 2003-04-25 | 2003-04-25 | |
| US46540803P | 2003-04-25 | 2003-04-25 | |
| US46560203P | 2003-04-25 | 2003-04-25 | |
| US46554803P | 2003-04-25 | 2003-04-25 | |
| US46554403P | 2003-04-25 | 2003-04-25 | |
| US60/465,478 | 2003-04-25 | ||
| US60/465,550 | 2003-04-25 | ||
| US60/465,602 | 2003-04-25 | ||
| US60/465,561 | 2003-04-25 | ||
| US60/465,548 | 2003-04-25 | ||
| US60/465,696 | 2003-04-25 | ||
| US60/465,544 | 2003-04-25 | ||
| US60/465,554 | 2003-04-25 | ||
| US60/465,598 | 2003-04-25 | ||
| US60/465,687 | 2003-04-25 | ||
| US60/465,584 | 2003-04-25 | ||
| US60/465,759 | 2003-04-25 | ||
| US60/465,608 | 2003-04-25 | ||
| US60/465,630 | 2003-04-25 | ||
| US60/465,821 | 2003-04-25 | ||
| US60/465,600 | 2003-04-25 | ||
| US60/465,610 | 2003-04-25 | ||
| US60/465,634 | 2003-04-25 | ||
| US60/465,377 | 2003-04-25 | ||
| US60/465,690 | 2003-04-25 | ||
| US60/465,591 | 2003-04-25 | ||
| US60/465,844 | 2003-04-25 | ||
| US60/465,289 | 2003-04-25 | ||
| US60/465,720 | 2003-04-25 | ||
| US60/465,537 | 2003-04-25 | ||
| US60/465,649 | 2003-04-25 | ||
| US60/465,469 | 2003-04-25 | ||
| US60/465,463 | 2003-04-25 | ||
| US60/465,400 | 2003-04-25 | ||
| US60/465,742 | 2003-04-25 | ||
| US60/465,347 | 2003-04-25 | ||
| US60/465,559 | 2003-04-25 | ||
| US60/465,633 | 2003-04-25 | ||
| US60/465,587 | 2003-04-25 | ||
| US60/465,684 | 2003-04-25 | ||
| US60/465,698 | 2003-04-25 | ||
| US60/465,553 | 2003-04-25 | ||
| US60/465,667 | 2003-04-25 | ||
| US60/465,647 | 2003-04-25 | ||
| US60/465,408 | 2003-04-25 | ||
| US60/465,322 | 2003-04-25 | ||
| US49079903P | 2003-07-29 | 2003-07-29 | |
| US60/490,799 | 2003-07-29 | ||
| US49580503P | 2003-08-15 | 2003-08-15 | |
| US49563003P | 2003-08-15 | 2003-08-15 | |
| US49559203P | 2003-08-15 | 2003-08-15 | |
| US49527303P | 2003-08-15 | 2003-08-15 | |
| US49534403P | 2003-08-15 | 2003-08-15 | |
| US49563103P | 2003-08-15 | 2003-08-15 | |
| US49568403P | 2003-08-15 | 2003-08-15 | |
| US49539303P | 2003-08-15 | 2003-08-15 | |
| US49534303P | 2003-08-15 | 2003-08-15 | |
| US49534203P | 2003-08-15 | 2003-08-15 | |
| US49549003P | 2003-08-15 | 2003-08-15 | |
| US49527703P | 2003-08-15 | 2003-08-15 | |
| US49560003P | 2003-08-15 | 2003-08-15 | |
| US49560203P | 2003-08-15 | 2003-08-15 | |
| US49569603P | 2003-08-15 | 2003-08-15 | |
| US49527503P | 2003-08-15 | 2003-08-15 | |
| US49527803P | 2003-08-15 | 2003-08-15 | |
| US49538703P | 2003-08-15 | 2003-08-15 | |
| US49563203P | 2003-08-15 | 2003-08-15 | |
| US49596403P | 2003-08-15 | 2003-08-15 | |
| US49533403P | 2003-08-15 | 2003-08-15 | |
| US49567103P | 2003-08-15 | 2003-08-15 | |
| US49542503P | 2003-08-15 | 2003-08-15 | |
| US49548503P | 2003-08-15 | 2003-08-15 | |
| US49576303P | 2003-08-15 | 2003-08-15 | |
| US49561603P | 2003-08-15 | 2003-08-15 | |
| US49553903P | 2003-08-15 | 2003-08-15 | |
| US49543003P | 2003-08-15 | 2003-08-15 | |
| US49576003P | 2003-08-15 | 2003-08-15 | |
| US49534503P | 2003-08-15 | 2003-08-15 | |
| US49539203P | 2003-08-15 | 2003-08-15 | |
| US49534103P | 2003-08-15 | 2003-08-15 | |
| US49534903P | 2003-08-15 | 2003-08-15 | |
| US49577203P | 2003-08-15 | 2003-08-15 | |
| US49538803P | 2003-08-15 | 2003-08-15 | |
| US49549103P | 2003-08-15 | 2003-08-15 | |
| US49556403P | 2003-08-15 | 2003-08-15 | |
| US49545303P | 2003-08-15 | 2003-08-15 | |
| US49563303P | 2003-08-15 | 2003-08-15 | |
| US49531703P | 2003-08-15 | 2003-08-15 | |
| US49568703P | 2003-08-15 | 2003-08-15 | |
| US60/495,772 | 2003-08-15 | ||
| US60/495,564 | 2003-08-15 | ||
| US60/495,278 | 2003-08-15 | ||
| US60/495,345 | 2003-08-15 | ||
| US60/495,602 | 2003-08-15 | ||
| US60/495,671 | 2003-08-15 | ||
| US60/495,600 | 2003-08-15 | ||
| US60/495,760 | 2003-08-15 | ||
| US60/495,341 | 2003-08-15 | ||
| US60/495,453 | 2003-08-15 | ||
| US60/495,696 | 2003-08-15 | ||
| US60/495,491 | 2003-08-15 | ||
| US60/495,631 | 2003-08-15 | ||
| US60/495,763 | 2003-08-15 | ||
| US60/495,684 | 2003-08-15 | ||
| US60/495,592 | 2003-08-15 | ||
| US60/495,344 | 2003-08-15 | ||
| US60/495,393 | 2003-08-15 | ||
| US60/495,317 | 2003-08-15 | ||
| US60/495,388 | 2003-08-15 | ||
| US60/495,277 | 2003-08-15 | ||
| US60/495,275 | 2003-08-15 | ||
| US60/495,633 | 2003-08-15 | ||
| US60/495,687 | 2003-08-15 | ||
| US60/495,425 | 2003-08-15 | ||
| US60/495,343 | 2003-08-15 | ||
| US60/495,342 | 2003-08-15 | ||
| US60/495,964 | 2003-08-15 | ||
| US60/495,632 | 2003-08-15 | ||
| US60/495,805 | 2003-08-15 | ||
| US60/495,630 | 2003-08-15 | ||
| US60/495,485 | 2003-08-15 | ||
| US60/495,273 | 2003-08-15 | ||
| US60/495,349 | 2003-08-15 | ||
| US60/495,616 | 2003-08-15 | ||
| US60/495,392 | 2003-08-15 | ||
| US60/495,387 | 2003-08-15 | ||
| US60/495,430 | 2003-08-15 | ||
| US60/495,334 | 2003-08-15 | ||
| US60/495,490 | 2003-08-15 | ||
| US60/495,539 | 2003-08-15 | ||
| US51024503P | 2003-10-10 | 2003-10-10 | |
| US60/510,245 | 2003-10-10 | ||
| US51425803P | 2003-10-24 | 2003-10-24 | |
| US51394803P | 2003-10-24 | 2003-10-24 | |
| US51420203P | 2003-10-24 | 2003-10-24 | |
| US60/514,202 | 2003-10-24 | ||
| US60/513,948 | 2003-10-24 | ||
| US60/514,258 | 2003-10-24 | ||
| US51526603P | 2003-10-29 | 2003-10-29 | |
| US60/515,266 | 2003-10-29 | ||
| US51947603P | 2003-11-12 | 2003-11-12 | |
| US60/519,476 | 2003-11-12 | ||
| US52434003P | 2003-11-20 | 2003-11-20 | |
| US60/524,340 | 2003-11-20 | ||
| US53259103P | 2003-12-23 | 2003-12-23 | |
| US60/532,591 | 2003-12-23 | ||
| PCT/US2004/013063 WO2004096286A2 (en) | 2003-04-25 | 2004-04-26 | Antiviral phosphonate analogs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007116237A Division JP2007238621A (ja) | 2003-04-25 | 2007-04-25 | 抗ウイルス性ホスホネート類似物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006524711A JP2006524711A (ja) | 2006-11-02 |
| JP2006524711A5 true JP2006524711A5 (https=) | 2007-06-28 |
| JP5069463B2 JP5069463B2 (ja) | 2012-11-07 |
Family
ID=33425965
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006513387A Expired - Lifetime JP5069463B2 (ja) | 2003-04-25 | 2004-04-26 | 抗ウイルス性ホスホネート類似物 |
| JP2007116237A Pending JP2007238621A (ja) | 2003-04-25 | 2007-04-25 | 抗ウイルス性ホスホネート類似物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007116237A Pending JP2007238621A (ja) | 2003-04-25 | 2007-04-25 | 抗ウイルス性ホスホネート類似物 |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US7429565B2 (https=) |
| EP (2) | EP2359833A1 (https=) |
| JP (2) | JP5069463B2 (https=) |
| AT (1) | ATE490788T1 (https=) |
| AU (1) | AU2004233898B2 (https=) |
| CA (1) | CA2523083C (https=) |
| CY (1) | CY1118836T1 (https=) |
| DK (1) | DK1628685T3 (https=) |
| EA (1) | EA014685B1 (https=) |
| IL (1) | IL170894A (https=) |
| MX (1) | MXPA05011297A (https=) |
| NO (1) | NO338306B1 (https=) |
| NZ (1) | NZ542342A (https=) |
| PL (1) | PL1628685T3 (https=) |
| PT (1) | PT1628685E (https=) |
| SG (1) | SG182849A1 (https=) |
| WO (1) | WO2004096286A2 (https=) |
Families Citing this family (236)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| JP2003007697A (ja) * | 2001-06-21 | 2003-01-10 | Hitachi Kokusai Electric Inc | 半導体装置の製造方法、基板処理方法および基板処理装置 |
| LT1576138T (lt) | 2002-11-15 | 2017-06-26 | Idenix Pharmaceuticals Llc | 2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija |
| EA014685B1 (ru) | 2003-04-25 | 2010-12-30 | Джилид Сайэнс, Инк. | Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе |
| HUE029877T2 (en) | 2003-05-30 | 2017-04-28 | Gilead Pharmasset Llc | Modified fluorinated nucleoside analogues |
| US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| CN101023094B (zh) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
| AU2005330489B2 (en) * | 2004-07-27 | 2011-08-25 | Gilead Sciences, Inc. | Nucleoside phosphonate conjugates as anti HIV agents |
| AU2011218664B2 (en) * | 2004-07-27 | 2014-08-21 | Gilead Sciences, Inc. | Antiviral compounds |
| US8492539B2 (en) | 2004-09-14 | 2013-07-23 | Gilead Pharmasset Llc | Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
| WO2006037090A2 (en) * | 2004-09-28 | 2006-04-06 | Purdue Research Foundation | Drug-phosphate conjugates as prodrugs |
| ES2401285T3 (es) | 2004-12-16 | 2013-04-18 | The Regents Of The University Of California | Fármacos con el pulmón como diana |
| WO2006104945A2 (en) | 2005-03-29 | 2006-10-05 | Biocryst Pharmaceuticals, Inc. | Hepatitis c therapies |
| ITRM20050391A1 (it) | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti analoghi della 6-tioguanosina trifosfato, loro uso in campo medico e procedimento per la loro preparazione. |
| MX2008001166A (es) | 2005-07-25 | 2008-03-18 | Intermune Inc | Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c. |
| EP1906971A2 (en) * | 2005-07-27 | 2008-04-09 | Gilead Sciences, Inc. | Antiviral compounds |
| AU2006301966A1 (en) * | 2005-10-11 | 2007-04-19 | Array Biopharma, Inc. | Compounds and methods for inhibiting hepatitis C viral replication |
| US8895531B2 (en) | 2006-03-23 | 2014-11-25 | Rfs Pharma Llc | 2′-fluoronucleoside phosphonates as antiviral agents |
| KR20090024834A (ko) * | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 억제제 |
| US7842672B2 (en) | 2006-07-07 | 2010-11-30 | Gilead Sciences, Inc. | Phosphonate inhibitors of HCV |
| US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
| MX2009007333A (es) | 2007-01-12 | 2009-08-31 | Biocryst Pharm Inc | Analogos de nucleosidos antivirales. |
| WO2008100447A2 (en) * | 2007-02-09 | 2008-08-21 | Gilead Sciences, Inc. | Nucleoside analogs for antiviral treatment |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| WO2008141227A1 (en) | 2007-05-10 | 2008-11-20 | Intermune, Inc. | Novel peptide inhibitors of hepatitis c virus replication |
| TW200942243A (en) | 2008-03-05 | 2009-10-16 | Biocryst Pharm Inc | Antiviral therapeutic agents |
| WO2009115927A2 (en) * | 2008-03-18 | 2009-09-24 | Institut De Recherches Cliniques De Montreal | Nucleotide analogues with quaternary carbon stereogenic centers and methods of use |
| EA201071034A1 (ru) | 2008-04-15 | 2011-06-30 | Интермьюн, Инк. | Новые макроциклические ингибиторы репликаций вируса гепатита с |
| HUE025528T2 (en) | 2008-04-23 | 2016-05-30 | Gilead Sciences Inc | 1'-substituted carba-nucleoside analogs for antiviral treatment |
| WO2010036407A2 (en) | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| AR072428A1 (es) * | 2008-07-01 | 2010-08-25 | Medivir Ab | Derivados de pirimidin nucleotidos inhibidores de polimerasas del virus de la hepatitis c (vhc), composiciones farmaceuticas que los contienen y metodo para prepararlos. |
| US8658617B2 (en) | 2008-07-08 | 2014-02-25 | Gilead Sciences, Inc. | Salts of HIV inhibitor compounds |
| CN102282155B (zh) | 2008-12-02 | 2017-06-09 | 日本波涛生命科学公司 | 磷原子修饰的核酸的合成方法 |
| PA8852101A1 (es) * | 2008-12-08 | 2010-07-27 | Medivir Ab | Nucleótidos uracil ciclopropílicos |
| AU2009329872B2 (en) | 2008-12-23 | 2016-07-07 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| NZ593649A (en) | 2008-12-23 | 2013-11-29 | Gilead Pharmasset Llc | Nucleoside analogs |
| PA8855601A1 (es) | 2008-12-23 | 2010-07-27 | Forformidatos de nucleósidos | |
| KR101150254B1 (ko) | 2008-12-26 | 2012-06-12 | 한미사이언스 주식회사 | 신규 중간체 및 이를 활용한 엔테카비르 제조방법 |
| AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| RU2612521C2 (ru) | 2009-07-06 | 2017-03-09 | Онтории, Инк. | Новые пролекарства нуклеиновых кислот и способы их применения |
| MX2012003126A (es) | 2009-09-21 | 2012-06-19 | Gilead Sciences Inc | Procesos e intermedios para la preparacion de analogos de 1'-carbonucleosidos sustituidos. |
| SG184324A1 (en) | 2010-03-31 | 2012-11-29 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
| EP2552203B1 (en) | 2010-04-01 | 2017-03-22 | Idenix Pharmaceuticals LLC. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| AU2011282241B2 (en) | 2010-07-19 | 2015-07-30 | Gilead Sciences, Inc. | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| ES2524356T3 (es) | 2010-07-22 | 2014-12-05 | Gilead Sciences, Inc. | Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae |
| NZ607996A (en) | 2010-09-22 | 2014-07-25 | Alios Biopharma Inc | Substituted nucleotide analogs |
| JP5868324B2 (ja) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
| CA2818853A1 (en) | 2010-11-30 | 2012-06-07 | Gilead Pharmasset Llc | 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus |
| US9243025B2 (en) | 2011-03-31 | 2016-01-26 | Idenix Pharmaceuticals, Llc | Compounds and pharmaceutical compositions for the treatment of viral infections |
| TWI635093B (zh) * | 2011-05-19 | 2018-09-11 | 基利科學股份有限公司 | 用於製備抗ｈｉｖ藥劑的方法與中間物 |
| AU2012278976B2 (en) | 2011-07-06 | 2017-05-11 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
| CN103796657B (zh) | 2011-07-19 | 2017-07-11 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| WO2013019874A1 (en) * | 2011-08-01 | 2013-02-07 | Mbc Pharma, Inc. | Vitamin b6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates |
| AR088441A1 (es) | 2011-09-12 | 2014-06-11 | Idenix Pharmaceuticals Inc | Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales |
| EP2709613B2 (en) | 2011-09-16 | 2020-08-12 | Gilead Pharmasset LLC | Methods for treating hcv |
| WO2013055252A1 (ru) * | 2011-10-14 | 2013-04-18 | Закрытое Акционерное Общество " Производственно-Коммерческая Ассоциация Азт" | Соли эфиров карбомоилфосфоновой кислоты, являющиеся селективными ингибиторами продукции вируса иммунодефицита человека вич-1 |
| US8507460B2 (en) | 2011-10-14 | 2013-08-13 | Idenix Pharmaceuticals, Inc. | Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| CA2860234A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
| HK1206362A1 (zh) | 2012-03-21 | 2016-01-08 | Alios Biopharma, Inc. | 硫代氨基磷酸酯核苷酸前藥的固體形式 |
| WO2013142157A1 (en) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
| US8859098B2 (en) * | 2012-05-18 | 2014-10-14 | Lord Corporation | Acrylic adhesion promoters |
| WO2013177188A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| JP6165848B2 (ja) | 2012-05-22 | 2017-07-19 | イデニク ファーマシューティカルズ エルエルシー | 肝疾患のためのｄ−アミノ酸化合物 |
| US9296778B2 (en) | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
| MX2014014323A (es) | 2012-05-25 | 2015-02-12 | Janssen R & D Ireland | Nucleosidos de espirooxetano de uracilo. |
| PL2872485T3 (pl) | 2012-07-13 | 2021-05-31 | Wave Life Sciences Ltd. | Asymetryczna grupa pomocnicza |
| ES2671478T3 (es) | 2012-08-31 | 2018-06-06 | Novartis Ag | Derivados de 2'-etinil nucleósidos para el tratamiento de infecciones virales |
| WO2014052638A1 (en) | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
| EP2906579B1 (en) | 2012-10-08 | 2018-04-18 | Idenix Pharmaceuticals LLC. | 2'-chloro nucleoside analogs for hcv infection |
| US10723754B2 (en) | 2012-10-22 | 2020-07-28 | Idenix Pharmaceuticals Llc | 2′,4′-bridged nucleosides for HCV infection |
| EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| EP2950786B1 (en) | 2013-01-31 | 2019-11-27 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| WO2014137930A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | Thiophosphate nucleosides for the treatment of hcv |
| WO2014137926A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | 3'-deoxy nucleosides for the treatment of hcv |
| AU2014225052B2 (en) * | 2013-03-08 | 2016-11-10 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Novel nucleoside phosphoramidate compound and use thereof |
| WO2014160484A1 (en) | 2013-03-13 | 2014-10-02 | Idenix Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
| SG10201800188SA (en) | 2013-03-15 | 2018-02-27 | Univ California | Acyclic nucleoside phosphonate diesters |
| EP2981542B1 (en) | 2013-04-01 | 2021-09-15 | Idenix Pharmaceuticals LLC | 2',4'-fluoro nucleosides for the treatment of hcv |
| US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
| WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
| PT3038601T (pt) | 2013-08-27 | 2020-06-30 | Gilead Pharmasset Llc | Formulação combinada de dois compostos antivirais |
| BR112016016400A2 (pt) | 2014-01-16 | 2017-10-03 | Wave Life Sciences Ltd | Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos |
| US10202411B2 (en) | 2014-04-16 | 2019-02-12 | Idenix Pharmaceuticals Llc | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV |
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| NO2717902T3 (https=) | 2014-06-20 | 2018-06-23 | ||
| WO2016036759A1 (en) | 2014-09-04 | 2016-03-10 | Gilead Sciences, Inc. | Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir |
| CN111808136B (zh) | 2014-09-15 | 2024-06-11 | 加利福尼亚大学董事会 | 核苷酸类似物 |
| TWI687432B (zh) | 2014-10-29 | 2020-03-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
| EP3214088B1 (en) | 2014-10-29 | 2020-02-26 | Tokyo University of Science Foundation | Method for producing eushearilides |
| TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| TWI699355B (zh) | 2014-12-24 | 2020-07-21 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| SG11201705192PA (en) | 2014-12-24 | 2017-07-28 | Gilead Sciences Inc | Fused pyrimidine compounds for the treatment of hiv |
| BR112017013440A2 (pt) | 2014-12-24 | 2018-01-09 | Gilead Sciences, Inc. | compostos de isoquinolina para o tratamento de hiv |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| WO2016134058A1 (en) * | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Combinations useful to treat hepatitis c virus |
| US9670205B2 (en) | 2015-03-04 | 2017-06-06 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| CA3182565A1 (en) | 2015-03-06 | 2016-09-15 | Atea Pharmaceuticals, Inc. | .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
| KR20190057158A (ko) | 2015-04-02 | 2019-05-27 | 길리애드 사이언시즈, 인코포레이티드 | 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도 |
| US20210292327A1 (en) | 2015-08-26 | 2021-09-23 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
| EP3350191B9 (en) | 2015-09-15 | 2021-12-22 | The Regents of the University of California | Nucleotide analogs |
| DK3785717T3 (da) | 2015-09-16 | 2022-03-21 | Gilead Sciences Inc | Fremgangsmåder til behandling af coronaviridae-infektioner |
| AU2016330895A1 (en) | 2015-09-30 | 2018-05-10 | Gilead Sciences, Inc. | Compounds and combinations for the treatment of HIV |
| JP6732915B2 (ja) | 2015-12-15 | 2020-07-29 | ギリアード サイエンシーズ， インコーポレイテッド | ヒト免疫不全ウイルス中和抗体 |
| US10390758B2 (en) * | 2016-03-24 | 2019-08-27 | Samsung Electronics Co., Ltd. | Method and apparatus for triage and subsequent escalation based on biosignals or biometrics |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
| WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| CN119462611A (zh) | 2016-08-19 | 2025-02-18 | 吉利德科学公司 | 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物 |
| WO2018042332A1 (en) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
| WO2018042331A1 (en) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
| HUE059718T2 (hu) | 2016-09-02 | 2022-12-28 | Dicerna Pharmaceuticals Inc | 4'-foszfát analógok és azokat tartalmazó oligonukleotidok |
| WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| AU2017318601B2 (en) | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| WO2018048937A1 (en) | 2016-09-07 | 2018-03-15 | Atea Pharmaceuticals, Inc. | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment |
| WO2018051250A1 (en) | 2016-09-14 | 2018-03-22 | Viiv Healthcare Company | Combination comprising tenofovir alafenamide, bictegravir and 3tc |
| EP3519409B1 (en) | 2016-09-28 | 2024-09-18 | Gilead Sciences, Inc. | Benzothiazol-6-yl acetic acid derivatives and their use for treating hiv infection |
| US10266558B2 (en) * | 2016-10-07 | 2019-04-23 | Alexandre Vasilievich Ivachtchenko | Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof |
| ES2881949T3 (es) | 2016-10-27 | 2021-11-30 | Gilead Sciences Inc | Forma cristalina de base libre de darunavir |
| TW202510891A (zh) | 2017-01-31 | 2025-03-16 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| IL288737B (en) | 2017-02-01 | 2022-09-01 | Atea Pharmaceuticals Inc | Hemisulfate nucleotide salt for treatment of hepatitis c virus |
| AR110922A1 (es) | 2017-02-06 | 2019-05-15 | Gilead Sciences Inc | Compuestos inhibidores del vih |
| US10682368B2 (en) | 2017-03-14 | 2020-06-16 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
| ES3003810T3 (en) | 2017-04-17 | 2025-03-11 | Univ Kyoto | Optically-active 2-amino-phosphonoalkane acid, optically-active 2-amino-phosphonoalkane acid salt, and hydrates of these |
| CA3059777C (en) | 2017-05-01 | 2023-02-21 | Gilead Sciences, Inc. | Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| WO2018230479A1 (ja) * | 2017-06-13 | 2018-12-20 | 大原薬品工業株式会社 | ヌクレオシド系抗がん剤又は抗ウィルス剤の５'位シリルエーテル誘導体 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| AR112257A1 (es) | 2017-06-21 | 2019-10-09 | Gilead Sciences Inc | Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos |
| WO2019014247A1 (en) | 2017-07-11 | 2019-01-17 | Gilead Sciences, Inc. | COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS |
| US10688112B2 (en) | 2017-07-13 | 2020-06-23 | Emory University | Lipid disulfide prodrugs and uses related thereto |
| SI3661937T1 (sl) | 2017-08-01 | 2021-11-30 | Gilead Sciences, Inc. | Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb |
| TWI687415B (zh) | 2017-08-17 | 2020-03-11 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| JOP20180092A1 (ar) | 2017-10-13 | 2019-04-13 | Gilead Sciences Inc | مثبطات hiv بروتياز |
| EP3700573A1 (en) | 2017-10-24 | 2020-09-02 | Gilead Sciences, Inc. | Methods of treating patients co-infected with a virus and tuberculosis |
| PT3706762T (pt) | 2017-12-07 | 2024-12-05 | Univ Emory | N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| JP7083398B2 (ja) | 2018-02-15 | 2022-06-10 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジン誘導体およびｈｉｖ感染を処置するためのその使用 |
| EP3752496B1 (en) | 2018-02-16 | 2023-07-05 | Gilead Sciences, Inc. | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| EP3773753A4 (en) | 2018-04-10 | 2021-12-22 | ATEA Pharmaceuticals, Inc. | TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| PL237998B1 (pl) | 2018-05-28 | 2021-06-28 | Narodowy Inst Lekow | Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie |
| DK4257600T3 (da) | 2018-07-03 | 2025-05-26 | Gilead Sciences Inc | Antistoffer rettet mod hiv gp120 og fremgangsmåder til at bruge dem |
| KR20210033492A (ko) | 2018-07-16 | 2021-03-26 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 치료를 위한 캡시드 억제제 |
| TWI829205B (zh) | 2018-07-30 | 2024-01-11 | 美商基利科學股份有限公司 | 抗hiv化合物 |
| EP3860717A1 (en) | 2018-10-03 | 2021-08-11 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| WO2020072931A2 (en) * | 2018-10-04 | 2020-04-09 | Octagon Therapeutics Inc. | Pre-activated nucleoside impdh inhibitors as anti-infective drugs |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| WO2020176510A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
| WO2020176505A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
| CN109761984B (zh) * | 2019-02-27 | 2020-07-07 | 河南师范大学 | 不对称氢转移合成手性五元碳环嘌呤核苷的方法 |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| MY201239A (en) | 2019-03-22 | 2024-02-13 | Gilead Sciences Inc | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| US20200347036A1 (en) | 2019-04-17 | 2020-11-05 | Gilead Sciences, Inc. | Solid forms of an hiv protease inhibitor |
| TW202104210A (zh) | 2019-04-17 | 2021-02-01 | 美商基利科學股份有限公司 | Hiv蛋白酶抑制劑 |
| WO2020227421A1 (en) | 2019-05-09 | 2020-11-12 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as sting modulators |
| TW202231277A (zh) | 2019-05-21 | 2022-08-16 | 美商基利科學股份有限公司 | 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| RU2717101C1 (ru) | 2019-06-03 | 2020-03-18 | Андрей Александрович Иващенко | Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения |
| CA3140708A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
| KR20240137107A (ko) | 2019-07-16 | 2024-09-19 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 백신, 및 이의 제조 및 사용 방법 |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| WO2021035214A1 (en) | 2019-08-22 | 2021-02-25 | Emory University | Nucleoside prodrugs and uses related thereto |
| CA3157275C (en) | 2019-11-26 | 2026-02-10 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of hiv |
| IL294032A (en) | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
| JP2023512656A (ja) | 2020-01-27 | 2023-03-28 | ギリアード サイエンシーズ， インコーポレイテッド | ＳＡＲＳ ＣｏＶ－２感染を治療するための方法 |
| PE20221569A1 (es) | 2020-02-24 | 2022-10-06 | Gilead Sciences Inc | Compuestos tetraciclicos para el tratamiento de infecciones por vih |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| KR20220153619A (ko) | 2020-03-12 | 2022-11-18 | 길리애드 사이언시즈, 인코포레이티드 | 1'-시아노 뉴클레오사이드의 제조 방법 |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| CA3172483A1 (en) | 2020-04-06 | 2021-10-14 | Scott Ellis | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| EP4153181A1 (en) | 2020-05-21 | 2023-03-29 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
| TW202203941A (zh) | 2020-05-29 | 2022-02-01 | 美商基利科學股份有限公司 | 瑞德西韋之治療方法 |
| PE20230618A1 (es) | 2020-06-24 | 2023-04-14 | Gilead Sciences Inc | Analogos de nucleosido de 1'-ciano y usos de los mismos |
| TWI858267B (zh) | 2020-06-25 | 2024-10-11 | 美商基利科學股份有限公司 | 用於治療hiv之蛋白殼抑制劑 |
| EP4192474B1 (en) | 2020-08-07 | 2025-09-10 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| IL300453A (en) | 2020-08-27 | 2023-04-01 | Gilead Sciences Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| ES3064867T3 (en) | 2020-09-30 | 2026-04-29 | Gilead Sciences Inc | Bridged tricyclic carbamoylpyridone compounds for a use in the treatment of hiv |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| PL4244396T3 (pl) | 2020-11-11 | 2025-12-22 | Gilead Sciences, Inc. | Sposoby identyfikacji pacjentów z hiv wrażliwych na terapię przeciwciałami skierowanymi na miejsce wiązania cd4 gp120 |
| US11613546B2 (en) | 2021-01-19 | 2023-03-28 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| IL308921A (en) | 2021-06-17 | 2024-01-01 | Atea Pharmaceuticals Inc | Combination anti-HCV therapy is beneficial |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| EP4389750A4 (en) | 2021-08-20 | 2025-10-01 | Shionogi & Co | NUCLEOSIDE DERIVATIVES AND THEIR PRODRUGS HAVING VIRAL GROWTH INHIBITORY ACTION |
| US12404262B2 (en) | 2021-12-03 | 2025-09-02 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
| US12084467B2 (en) | 2021-12-03 | 2024-09-10 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
| CR20240223A (es) | 2021-12-03 | 2024-07-08 | Gilead Sciences Inc | Compuestos terapéuticos para la infección por el virus del vih |
| KR20240154647A (ko) | 2022-03-02 | 2024-10-25 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스성 감염 치료를 위한 화합물 및 방법 |
| TW202446773A (zh) | 2022-04-06 | 2024-12-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| TWI867601B (zh) | 2022-07-01 | 2024-12-21 | 美商基利科學股份有限公司 | 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物 |
| CA3259040A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | HIV Immunogenic Polypeptides and Vaccines and Their Uses |
| KR20250052378A (ko) | 2022-07-21 | 2025-04-18 | 안티바 바이오사이언시즈, 인크. | Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태 |
| AU2023330037A1 (en) | 2022-08-26 | 2025-03-06 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
| US20240226130A1 (en) | 2022-10-04 | 2024-07-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
| US20240390349A1 (en) | 2023-04-19 | 2024-11-28 | Gilead Sciences, Inc. | Dosing regimen of capsid inhibitor |
| CN121219281A (zh) | 2023-05-31 | 2025-12-26 | 吉利德科学公司 | 用于治疗hiv的化合物的固体形式 |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| US20250051375A1 (en) | 2023-05-31 | 2025-02-13 | Gilead Sciences, Inc. | Anti-hiv compounds |
| WO2025029247A1 (en) | 2023-07-28 | 2025-02-06 | Gilead Sciences, Inc. | Weekly regimen of lenacapavir for the treatment and prevention of hiv |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| WO2025076542A1 (en) | 2023-10-05 | 2025-04-10 | Jones R Brad | Atovaquone as an ros inducer for use in the elimination of hiv-infected t-cells |
| US20250122219A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| TW202515549A (zh) | 2023-10-11 | 2025-04-16 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| US20250127801A1 (en) | 2023-10-11 | 2025-04-24 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| US20250230163A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250333424A1 (en) | 2024-03-01 | 2025-10-30 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2025184452A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250296932A1 (en) | 2024-03-01 | 2025-09-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| WO2025212814A1 (en) | 2024-04-03 | 2025-10-09 | Gilead Sciences, Inc. | Anti-hiv compounds |
| WO2025240608A1 (en) * | 2024-05-14 | 2025-11-20 | Rome Therapeutics, Inc. | Cyclo-oxymethylene phosphonamidates and related compounds and their use in treating medical conditions |
| US20260007683A1 (en) | 2024-06-14 | 2026-01-08 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| WO2026005773A1 (en) * | 2024-06-26 | 2026-01-02 | Ads Therapeutics Llc | Method for preparing compounds containing fluorine |
| WO2026076265A1 (en) | 2024-10-03 | 2026-04-09 | Gilead Sciences, Inc. | Combination therapy comprising bridged tricyclic carbamoylpyridone compounds and p-glycoprotein inhibitors |
Family Cites Families (166)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4649041A (en) | 1983-07-20 | 1987-03-10 | Warner-Lambert Company | Magnesium trisilicate suitable for preparation of medicament adsorbates of antinauseants |
| DK159431C (da) | 1984-05-10 | 1991-03-18 | Byk Gulden Lomberg Chem Fab | 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| US5455339A (en) | 1986-05-01 | 1995-10-03 | University Of Georgia Research Foundation, Inc. | Method for the preparation of 2',3'-dideoxy and 2',3'-dideoxydide-hydro nucleosides |
| IE63869B1 (en) | 1986-11-06 | 1995-06-14 | Res Dev Foundation | Aerosols containing liposomes and method for their preparation |
| FR2611203B1 (fr) | 1987-02-20 | 1989-06-09 | Sturtz Georges | Analogues gem-diphosphoniques d'amethopterine (methotrexate) et de derives deaza-n-10 amethopterine. leur preparation et les compositions pharmaceutiques qui les contiennent |
| US5631370A (en) * | 1988-01-20 | 1997-05-20 | Regents Of The University Of Minnesota | Optically-active isomers of dideoxycarbocyclic nucleosides |
| US5466793A (en) | 1988-03-01 | 1995-11-14 | Ajinomoto Co., Inc. | Process for preparing 2', 3'- dideoxyinosine |
| ZA894534B (en) | 1988-06-20 | 1990-03-28 | Merrell Dow Pharma | Novel neplanocin derivatives |
| CA2001715C (en) | 1988-11-14 | 1999-12-28 | Muzammil M. Mansuri | Carbocyclic nucleosides and nucleotides |
| US5744600A (en) | 1988-11-14 | 1998-04-28 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Phosphonomethoxy carbocyclic nucleosides and nucleotides |
| US5202128A (en) | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
| JP2722673B2 (ja) * | 1989-05-31 | 1998-03-04 | 住友化学工業株式会社 | 光学活性なアシルビフェニル誘導体の製造法 |
| DE4003574A1 (de) | 1990-02-07 | 1991-08-08 | Bayer Ag | Neue dipeptide, verfahren zu ihrer herstellung und ihre verwendung als renininhibitoren in arzneimitteln |
| JPH0690744B2 (ja) | 1990-05-24 | 1994-11-14 | 四国旅客鉄道株式会社 | 乗車券類発売機 |
| EP0533833B1 (en) | 1990-06-13 | 1995-12-20 | GLAZIER, Arnold | Phosphorous produgs |
| EP0465297B1 (en) | 1990-07-04 | 1996-01-31 | Merrell Dow Pharmaceuticals Inc. | 9-Purinyl phosphonic acid derivatives |
| US5177064A (en) | 1990-07-13 | 1993-01-05 | University Of Florida | Targeted drug delivery via phosphonate derivatives |
| EP0468119A1 (en) | 1990-07-24 | 1992-01-29 | Merrell Dow Pharmaceuticals Inc. | Novel carbocyclic analogs of certain nucleosides |
| US6087482A (en) | 1990-07-27 | 2000-07-11 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
| US5223618A (en) * | 1990-08-13 | 1993-06-29 | Isis Pharmaceuticals, Inc. | 4'-desmethyl nucleoside analog compounds |
| EP0481214B1 (en) | 1990-09-14 | 1998-06-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Prodrugs of phosphonates |
| US5672697A (en) | 1991-02-08 | 1997-09-30 | Gilead Sciences, Inc. | Nucleoside 5'-methylene phosphonates |
| DE4111730A1 (de) | 1991-04-10 | 1992-10-15 | Knoll Ag | Neue cytarabin-derivate, ihre herstellung und verwendung |
| JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| EP0531597A1 (en) | 1991-09-12 | 1993-03-17 | Merrell Dow Pharmaceuticals Inc. | Novel unsaturated acyclic phosphonate derivatives of purine and pyrimidine |
| US5610294A (en) * | 1991-10-11 | 1997-03-11 | The Du Pont Merck Pharmaceutical Company | Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors |
| DE4138584A1 (de) * | 1991-11-23 | 1993-05-27 | Hoechst Ag | Carbocyclische phosphonat-nucleotidanaloge, deren herstellung und verwendung |
| GB9126144D0 (en) | 1991-12-10 | 1992-02-12 | British Bio Technology | Compounds |
| FR2692265B1 (fr) | 1992-05-25 | 1996-11-08 | Centre Nat Rech Scient | Composes biologiquement actifs de type phosphotriesters. |
| IS2334B (is) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| DE4308096A1 (de) | 1993-03-13 | 1994-09-15 | Hoechst Ag | Prodrug-Derivate von Enzyminhibitoren mit Hydroxylgruppen, Verfahren zu deren Herstellung und ihre Verwendung |
| US5654286A (en) * | 1993-05-12 | 1997-08-05 | Hostetler; Karl Y. | Nucleotides for topical treatment of psoriasis, and methods for using same |
| ATE199906T1 (de) * | 1993-06-29 | 2001-04-15 | Mitsubishi Chem Corp | Phosphonat-nukleotid ester-derivate |
| EP0708760A1 (en) * | 1993-07-14 | 1996-05-01 | Novartis AG | Cyclic hydrazine compounds |
| CN1090328C (zh) * | 1993-08-24 | 2002-09-04 | 阿克佐诺贝尔公司 | 眼镜片 |
| EP0719273B1 (en) | 1993-09-17 | 2010-11-03 | Gilead Sciences, Inc. | Nucleotide analogs |
| US5656745A (en) * | 1993-09-17 | 1997-08-12 | Gilead Sciences, Inc. | Nucleotide analogs |
| US5446137B1 (en) * | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
| US5493030A (en) * | 1994-02-18 | 1996-02-20 | Syntex (U.S.A.) Inc. | 5-substituted derivatives of mycophenolic acid |
| US5854227A (en) | 1994-03-04 | 1998-12-29 | Hartmann; John F. | Therapeutic derivatives of diphosphonates |
| WO1997011092A1 (en) | 1994-04-07 | 1997-03-27 | Nippon Shinyaku Co., Ltd. | Cyclosporin phosphate derivatives and medicinal composition |
| DK0786455T3 (da) | 1994-09-26 | 2004-03-29 | Shionogi & Co | Imidazolderivater |
| EP0789695A2 (en) | 1994-11-04 | 1997-08-20 | Gilead Sciences, Inc. | Thiepane compounds inhibiting and detecting hiv protease |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| ES2097703B1 (es) | 1995-04-12 | 1997-12-01 | Decox S L | Una nueva composicion estimulante de la actividad cerebral basada en alcaloides de nucleo de eburnamenina, y sus metodos de preparacion. |
| US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| JPH11508541A (ja) | 1995-06-29 | 1999-07-27 | ノボ ノルディスク アクティーゼルスカブ | 新規な置換アザ二環式化合物 |
| US5750493A (en) * | 1995-08-30 | 1998-05-12 | Raymond F. Schinazi | Method to improve the biological and antiviral activity of protease inhibitors |
| US5914332A (en) * | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5859233A (en) | 1996-02-21 | 1999-01-12 | Lynx Therapeutics, Inc. | Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates |
| US5684143A (en) | 1996-02-21 | 1997-11-04 | Lynx Therapeutics, Inc. | Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates |
| RU2106353C1 (ru) | 1996-03-19 | 1998-03-10 | Корпорация "С энд Ти Сайенс энд Текнолоджи Инк." | Соли 5'-н-фосфоната 3'- азидо-3'-дезокситимидина, являющиеся специфическими ингибиторами продукции вируса иммунодефицита человека вич-1 и вич-2 |
| US5874577A (en) * | 1996-04-03 | 1999-02-23 | Medichem Research, Inc. | Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof |
| US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| CA2261619C (en) | 1996-07-26 | 2006-05-23 | Gilead Sciences, Inc. | Nucleotide analogs |
| US6194398B1 (en) * | 1996-08-13 | 2001-02-27 | Mitsubishi Chemical Corporation | Phosphonate nucleotide compound |
| EP0948341A4 (en) | 1996-09-17 | 2003-05-21 | Supergen Inc | DERIVATIVES OF PHOSPHOLIPIDE MEDICINES |
| BR9712285A (pt) | 1996-10-09 | 2001-11-20 | Pharmasset Ltd | Tetrafosfonato bicìclico de trianidridas |
| EP0994106B1 (en) | 1996-12-26 | 2004-03-17 | Shionogi & Co., Ltd. | Process for the preparation of carbamoylated imidazole derivatives |
| AU1810399A (en) | 1997-12-10 | 1999-06-28 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Method for synthesizing |
| US6436989B1 (en) | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| US6174888B1 (en) * | 1998-05-28 | 2001-01-16 | Novartis Ag | 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydropyrrolo[3,2-D]pyrimidin-4-ones |
| WO1999062921A1 (en) | 1998-06-01 | 1999-12-09 | S & T Science And Technology Inc. | Antiviral phosphorus derivatives of 4'-thio-5-ethyl-2'-deoxyuridine |
| GB9815567D0 (en) | 1998-07-18 | 1998-09-16 | Glaxo Group Ltd | Antiviral compound |
| TNSN00027A1 (fr) * | 1999-02-12 | 2005-11-10 | Vertex Pharma | Inhibiteurs de l'aspartyle protease |
| US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| MXPA01008937A (es) | 1999-03-05 | 2004-04-05 | Metabasis Therapeutics Inc | Nuevos profarmacos que contienen fosforo. |
| DE19912636A1 (de) * | 1999-03-20 | 2000-09-21 | Aventis Cropscience Gmbh | Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel |
| US6258831B1 (en) | 1999-03-31 | 2001-07-10 | The Procter & Gamble Company | Viral treatment |
| US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| DE19927689A1 (de) | 1999-06-17 | 2000-12-21 | Gruenenthal Gmbh | Orale Darreichungsformen zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac |
| ATE248835T1 (de) * | 1999-06-25 | 2003-09-15 | Vertex Pharma | Prodrugs von impdh-inhibierenden carbamaten |
| US6581606B2 (en) | 1999-07-06 | 2003-06-24 | The Rx Files Corporation | Method, apparatus and system for use in treating patient with a drug having an antineoplastic effect to optimize therapy and prevent an adverse drug response |
| US6593292B1 (en) | 1999-08-24 | 2003-07-15 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| GB9920872D0 (en) | 1999-09-04 | 1999-11-10 | Glaxo Group Ltd | Benzophenones as inhibitors of reverse transcriptase |
| IL131887A0 (en) | 1999-09-14 | 2001-03-19 | Dpharm Ltd | Phospholipid prodrugs of anti-proliferative drugs |
| CA2747954C (en) | 1999-12-03 | 2014-02-25 | The Regents Of The University Of California | Phosphonate compounds |
| AU784370B2 (en) | 1999-12-22 | 2006-03-23 | Metabasis Therapeutics, Inc. | Novel bisamidate phosphonate prodrugs |
| JP2003518128A (ja) | 1999-12-22 | 2003-06-03 | メルク フロスト カナダ アンド カンパニー | タンパク質チロシンホスファターゼ１ｂ（ｐｔｐ−１ｂ）のインヒビターとなる芳香族ホスホネート |
| CN1426418A (zh) * | 2000-02-29 | 2003-06-25 | 三菱制药株式会社 | 膦酸酯核苷酸化合物 |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| AP2003002716A0 (en) | 2000-06-13 | 2003-06-30 | Shionogi & Co | Medicinal compositions containing propenone derivatives. |
| FR2810322B1 (fr) | 2000-06-14 | 2006-11-10 | Pasteur Institut | PRODUCTION COMBINATOIRE D'ANALOGUES DE NUCLEOTIDES ET NUCLEOTIDES (XiTP) |
| UA72612C2 (en) | 2000-07-06 | 2005-03-15 | Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells | |
| US6617310B2 (en) | 2000-07-19 | 2003-09-09 | Bristol-Myers Squibb Pharma Company | Phosphate esters of bis-amino acid sulfonamides containing substituted benzyl amines |
| US20020119443A1 (en) * | 2000-07-21 | 2002-08-29 | Gilead Sciences, Inc. | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| US6420586B1 (en) | 2000-08-15 | 2002-07-16 | University Of Kansas | Amino acid-derived cyclic phosphonamides and methods of synthesizing the same |
| AU5668501A (en) | 2000-09-08 | 2002-03-22 | Zeria Pharm Co Ltd | Pharmaceutical compositions containing aminothiazole derivatives for the treatment of colonic motor dysfunctions |
| RU2188203C2 (ru) | 2000-10-05 | 2002-08-27 | Государственный научный центр вирусологии и биотехнологии "Вектор" | 2',3'-дидегидро-2',3'-дидезокситимидин-5'[(этоксикарбонил)(этил)фосфонат]- ингибитор репродукции вируса иммунодефицита человека |
| GB0028429D0 (en) | 2000-11-22 | 2001-01-10 | Astrazeneca Ab | Therapy |
| WO2002048165A2 (en) | 2000-12-15 | 2002-06-20 | Pharmasset Ltd. | Antiviral agents for treatment of flaviviridae infections |
| ATE431830T1 (de) | 2000-12-28 | 2009-06-15 | Kissei Pharmaceutical | Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln |
| SK286630B6 (sk) * | 2001-01-22 | 2009-02-05 | Merck & Co., Inc. | Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie |
| MXPA03005403A (es) | 2001-01-31 | 2003-09-25 | Warner Lambert Co | Metodo para carbamoilar alcoholes. |
| AU2002250058B2 (en) | 2001-02-12 | 2007-08-16 | Wyeth Llc | Novel succinate salt of O-desmethyl-venlafaxine |
| EP1262458B1 (en) | 2001-05-31 | 2008-03-05 | Sumitomo Chemical Company, Limited | Method for producing an activated alumina formed body |
| GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| IL159268A0 (en) | 2001-06-20 | 2004-06-01 | Nuevolution As | Templated molecules and methods for using such molecules |
| KR20020097384A (ko) * | 2001-06-20 | 2002-12-31 | 미쯔비시 도꾜 세이야꾸 가부시끼가이샤 | 기존의 약제에 내성변이를 가지는 바이러스에 유효한 약제 |
| WO2003009855A2 (de) | 2001-07-20 | 2003-02-06 | Bioagency Ag | Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen |
| CN1543455B (zh) | 2001-08-17 | 2012-07-11 | 三井化学Agro株式会社 | 3-苯氧基-4-哒嗪醇衍生物以及含有它的除草剂组合物 |
| WO2003028737A1 (en) | 2001-08-30 | 2003-04-10 | Mitsubishi Pharma Corporation | Anti-viral agents and in-vitro method for the identification of candidates able to inhibit binding of polymerase to epsilon |
| EP1461040B1 (en) | 2001-11-29 | 2006-03-15 | Pfizer Products Inc. | Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof |
| JP2005511749A (ja) | 2001-12-07 | 2005-04-28 | 三菱ウェルファーマ株式会社 | Ｂ型肝炎ウィルス感染症を治療するためのホスホネートヌクレオチド類似体の使用 |
| PL370858A1 (en) | 2001-12-12 | 2005-05-30 | Pfizer Products Inc. | Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production |
| JP4369237B2 (ja) | 2001-12-21 | 2009-11-18 | エーザイ コーポレーション オブ ノース アメリカ | アルコールおよびフェノールの水溶性ホスホノオキシメチル誘導体の調製法 |
| US20030198666A1 (en) | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| PT1478648E (pt) | 2002-02-01 | 2014-07-15 | Ariad Pharma Inc | Compostos contendo fósforo e suas utilizações |
| WO2003066005A2 (en) | 2002-02-08 | 2003-08-14 | Conforma Therapeutics Corporation | Ansamycins having improved pharmacological and biological properties |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| AU2003216523A1 (en) | 2002-03-18 | 2003-10-08 | Mitsubishi Pharma Corporation | Treatment of pre-core hepatitis b virus mutant infections |
| JP2005525398A (ja) | 2002-04-10 | 2005-08-25 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | ブラジキニン受容体モジュレーターとして有用な新規なヘテロアリールアルキルアミド誘導体 |
| US20050239054A1 (en) | 2002-04-26 | 2005-10-27 | Arimilli Murty N | Method and compositions for identifying anti-HIV therapeutic compounds |
| US6872827B2 (en) | 2002-04-26 | 2005-03-29 | Chembridge Research Laboratories, Inc. | Somatostatin analogue compounds |
| WO2003091264A2 (en) | 2002-04-26 | 2003-11-06 | Gilead Sciences, Inc. | Non nucleoside reverse transcriptase inhibitors |
| CA2534968C (en) * | 2002-09-20 | 2013-06-18 | M7 Visual Intelligence, Lp | Vehicle based data collection and processing system |
| EP1832583A1 (en) | 2002-09-30 | 2007-09-12 | A/S GEA Farmaceutisk Fabrik | Novel raloxifene sulphuric acid addition salts and/or solvates thereof, and pharmaceutical compositions comprising these |
| US20040157793A1 (en) | 2002-11-12 | 2004-08-12 | Stuyver Lieven J. | Modified nucleosides as antiviral agents |
| CN102174038A (zh) | 2003-02-19 | 2011-09-07 | 耶鲁大学 | 用于治疗病毒感染的抗病毒核苷 |
| MXPA05011294A (es) | 2003-04-25 | 2006-03-15 | Gilead Sciences Inc | Compuestos de fosfonato anti-inflamatorios. |
| WO2004096236A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Immunomodulator phosphonate conjugates |
| US7470724B2 (en) | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
| US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
| KR20060022647A (ko) | 2003-04-25 | 2006-03-10 | 길리애드 사이언시즈, 인코포레이티드 | 키나아제 억제 포스포네이트 유사체 |
| US7407965B2 (en) | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
| US7427636B2 (en) | 2003-04-25 | 2008-09-23 | Gilead Sciences, Inc. | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
| WO2004096237A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
| US7300924B2 (en) | 2003-04-25 | 2007-11-27 | Gilead Sciences, Inc. | Anti-infective phosphonate analogs |
| WO2004096233A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Nucleoside phosphonate conjugates |
| CN101410120A (zh) | 2003-04-25 | 2009-04-15 | 吉里德科学公司 | 抗炎的膦酸酯化合物 |
| US7432261B2 (en) | 2003-04-25 | 2008-10-07 | Gilead Sciences, Inc. | Anti-inflammatory phosphonate compounds |
| EA014685B1 (ru) | 2003-04-25 | 2010-12-30 | Джилид Сайэнс, Инк. | Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе |
| BRPI0409680A (pt) * | 2003-04-25 | 2006-04-18 | Gilead Sciences Inc | análogos de fosfonato anti-cáncer |
| WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
| WO2005000786A1 (en) | 2003-05-23 | 2005-01-06 | Transform Pharmaceuticals, Inc. | Sertraline compositions |
| CA2727748A1 (en) | 2003-06-16 | 2004-12-23 | Ajinomoto Co., Inc. | Inosine derivatives and production methods therefor |
| US20060252729A1 (en) | 2003-07-30 | 2006-11-09 | Krawczyk Steven H | Nucleobase phosphonate analogs for antiviral treatment |
| PL1658277T3 (pl) | 2003-08-18 | 2012-10-31 | H Lundbeck As | Sól bursztynianowa i malonianowa trans-4-((1R,3S)-6-chloro-3-fenyloindan-1-ylo)-1,2,2-tri-metylopiperazyny i zastosowanie jako lek |
| WO2005044308A1 (en) | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Phosphonate analogs of antimetabolites |
| WO2005042773A1 (en) | 2003-10-24 | 2005-05-12 | Gilead Sciences, Inc. | Methods and compositions for identifying therapeutic compounds |
| WO2005044279A1 (en) | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Purine nucleoside phosphonate conjugates |
| BRPI0417988A (pt) | 2003-12-22 | 2007-04-27 | Gilead Sciences Inc | análogos de fosfonato antivirais |
| WO2005063258A1 (en) | 2003-12-22 | 2005-07-14 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
| US20050171126A1 (en) | 2003-12-26 | 2005-08-04 | Ajinomoto Co., Inc. | Process for the production of purine nucleoside compounds |
| US7404949B2 (en) | 2004-03-15 | 2008-07-29 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Methods and compositions useful to prevent in-grown hair arising from shaving |
| US20090035315A1 (en) | 2004-06-17 | 2009-02-05 | Stephan Christgau | Method of Improving Treatments in Rheumatic and Arthritic Diseases |
| AU2005330489B2 (en) | 2004-07-27 | 2011-08-25 | Gilead Sciences, Inc. | Nucleoside phosphonate conjugates as anti HIV agents |
| WO2006015262A2 (en) | 2004-07-29 | 2006-02-09 | Coherix, Inc. | Method for processing multiwavelength interferometric imaging data |
| US20060069060A1 (en) | 2004-09-27 | 2006-03-30 | Sanjeev Redkar | Salts of decitabine |
| US7154505B2 (en) | 2004-11-11 | 2006-12-26 | Stonecube Limited | Method of and apparatus for generating a representation of an object |
| KR20060080817A (ko) | 2005-01-06 | 2006-07-11 | 씨제이 주식회사 | 시부트라민의 디카복실산염 |
| MY148074A (en) | 2005-05-10 | 2013-02-28 | Novartis Ag | Pharmaceutical compositions comprising imatinib and a release retardant |
| AU2006278596A1 (en) | 2005-08-04 | 2007-02-15 | Novartis Ag | Salts of vildagliptin |
| DE102005041860A1 (de) | 2005-09-02 | 2007-03-08 | Schering Ag | Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen |
| TW200730530A (en) | 2005-12-16 | 2007-08-16 | Wyeth Corp | Lyophilized compositions of a triazolopyrimidine compound |
| US20060223820A1 (en) | 2006-03-21 | 2006-10-05 | Chemagis Ltd. | Crystalline aripiprazole salts and processes for preparation and purification thereof |
| US8895531B2 (en) | 2006-03-23 | 2014-11-25 | Rfs Pharma Llc | 2′-fluoronucleoside phosphonates as antiviral agents |
| MX2009008935A (es) | 2007-02-23 | 2009-11-02 | Gilead Sciences Inc | Moduladores de las propiedades farmacocineticas de productos terapeuticos. |
| US20090163449A1 (en) | 2007-12-20 | 2009-06-25 | Eastman Chemical Company | Sulfo-polymer powder and sulfo-polymer powder blends with carriers and/or additives |
| US8658617B2 (en) | 2008-07-08 | 2014-02-25 | Gilead Sciences, Inc. | Salts of HIV inhibitor compounds |
| EP2305680A3 (en) | 2009-09-30 | 2011-05-18 | Aurobindo Pharma Limited | Novel salts of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol |
| WO2014055603A1 (en) | 2012-10-03 | 2014-04-10 | Gilead Sciences, Inc. | Process for the preparation of an hiv integrase inhibitor |
| WO2014055618A1 (en) | 2012-10-03 | 2014-04-10 | Gilead Sciences, Inc. | Solid state forms of hiv inhibitor: hemi-succinate of (2s)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid) |
-
2004
- 2004-04-26 EA EA200501680A patent/EA014685B1/ru unknown
- 2004-04-26 PT PT04750807T patent/PT1628685E/pt unknown
- 2004-04-26 NZ NZ542342A patent/NZ542342A/en not_active IP Right Cessation
- 2004-04-26 EP EP20100184722 patent/EP2359833A1/en not_active Withdrawn
- 2004-04-26 MX MXPA05011297A patent/MXPA05011297A/es active IP Right Grant
- 2004-04-26 AU AU2004233898A patent/AU2004233898B2/en not_active Expired
- 2004-04-26 CA CA 2523083 patent/CA2523083C/en not_active Expired - Lifetime
- 2004-04-26 SG SG2007175052A patent/SG182849A1/en unknown
- 2004-04-26 JP JP2006513387A patent/JP5069463B2/ja not_active Expired - Lifetime
- 2004-04-26 AT AT04750807T patent/ATE490788T1/de active
- 2004-04-26 DK DK04750807.2T patent/DK1628685T3/da active
- 2004-04-26 US US10/832,815 patent/US7429565B2/en not_active Expired - Lifetime
- 2004-04-26 WO PCT/US2004/013063 patent/WO2004096286A2/en not_active Ceased
- 2004-04-26 EP EP04750807A patent/EP1628685B1/en not_active Expired - Lifetime
- 2004-04-26 PL PL04750807T patent/PL1628685T3/pl unknown
-
2005
- 2005-09-15 IL IL170894A patent/IL170894A/en active IP Right Grant
- 2005-11-25 NO NO20055591A patent/NO338306B1/no unknown
-
2007
- 2007-04-25 JP JP2007116237A patent/JP2007238621A/ja active Pending
-
2008
- 2008-07-01 US US12/166,076 patent/US8022083B2/en not_active Expired - Lifetime
-
2011
- 2011-03-04 CY CY20111100258T patent/CY1118836T1/el unknown
- 2011-07-20 US US13/187,293 patent/US20110288053A1/en not_active Abandoned
-
2013
- 2013-03-21 US US13/848,593 patent/US8871785B2/en not_active Expired - Lifetime
-
2014
- 2014-06-19 US US14/309,790 patent/US9139604B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006524711A5 (https=) | ||
| EP3740487B1 (en) | Benzamide compounds as bci inhibitors for the treatment of hiv | |
| AU2004206821C1 (en) | Compositions and methods for combination antiviral therapy | |
| AU2011349278C1 (en) | Cyclic nucleotide analogs | |
| ES2649410T3 (es) | Agentes antivirales para la hepatitis B | |
| JP2003514771A5 (https=) | ||
| WO2013142159A1 (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
| CA2952959A1 (en) | Use of nucleosides and nucleotides to treat filoviridae viral infection | |
| PT2595980E (pt) | Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae | |
| WO2007097991A2 (en) | Methods and kits for dosing of antiviral agents | |
| US11306399B2 (en) | Nanoparticle compositions | |
| US10266558B2 (en) | Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof | |
| KR100632520B1 (ko) | Β 형 간염 바이러스를 치료하기 위한 복합 요법 | |
| JP2007515495A5 (https=) | ||
| US20090258843A1 (en) | Compositions Containing Antiviral Compounds and Methods of Using the Same | |
| BR112021010236A2 (pt) | Análogos de ciclobutil nucleosídeos como antivirais | |
| ZA200505852B (en) | Compositions and methods for combination antiviraltherapy | |
| ES2993261T3 (en) | Spirocyclic inhibitors of hepatitis b virus | |
| HK40040853A (en) | Benzamide compounds as bci inhibitors for the treatment of hiv | |
| HK40040853B (en) | Benzamide compounds as bci inhibitors for the treatment of hiv | |
| HK40074766B (en) | Macrocyclic compounds as sting agonists and methods and uses thereof | |
| HK40074766A (en) | Macrocyclic compounds as sting agonists and methods and uses thereof | |
| HK1224587A1 (en) | Compositions and methods for combination antiviral therapy | |
| HK1119590A (en) | Compositions and methods for combination antiviral therapy | |
| JP2007500743A5 (https=) |